Stay updated on XmAb®22841 in Advanced Solid Tumors Clinical Trial
Sign up to get notified when there's something new on the XmAb®22841 in Advanced Solid Tumors Clinical Trial page.

Latest updates to the XmAb®22841 in Advanced Solid Tumors Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoNo Change Detected
- Check19 days agoChange DetectedThe history now shows a new site revision (v3.6.3) and the previous revision (v3.6.2) is removed, indicating a platform update to how revisions are tracked on the page.SummaryDifference0.1%

- Check26 days agoChange DetectedA new revision entry 'Revision: v3.6.2' was added to the study record history, and the previous 'Revision: v3.6.0' entry was removed. This reflects an update to the version history metadata for the record.SummaryDifference0.1%

- Check40 days agoChange DetectedAdded a recruitment note 'No longer looking for participants'; updated the page revision to v3.6.0, replacing the previous v3.5.5.SummaryDifference0.4%

- Check47 days agoChange DetectedAdded a new revision entry v3.5.5 and removed the previous entry v3.5.4 from the revision history list. This update adjusts the visible revision history for the study record.SummaryDifference0.1%

- Check69 days agoChange DetectedAdded a new revision entry v3.5.4 to the Record History and removed the previous v3.5.3 entry, updating the history to reflect the latest revision of the study record. This update records the latest release in the log without altering study data or functionality.SummaryDifference0.1%

- Check90 days agoChange DetectedThe page’s footer has been updated to indicate a newer ClinicalTrials.gov revision/version (v3.5.3 instead of v3.5.2). This reflects a platform/release update rather than a change to the underlying clinical trial record.SummaryDifference0.1%

Stay in the know with updates to XmAb®22841 in Advanced Solid Tumors Clinical Trial
Enter your email address, and we'll notify you when there's something new on the XmAb®22841 in Advanced Solid Tumors Clinical Trial page.